Status:
COMPLETED
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
Lead Sponsor:
UCB Biopharma SRL
Conditions:
Chronic Plaque Psoriasis
Moderate to Severe Chronic Plaque Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks afte...
Eligibility Criteria
Inclusion
- Subject fulfills all inclusion criteria for the PS0014 \[NCT03598790\] study
- Subject is considered reliable and capable of adhering to the DV0002 protocol (eg, able to understand and complete questionnaires, willing to self-inject, able to use investigational device according to the instructions for use (IFU), and able to adhere to the visit schedule) according to the judgment of the Investigator
Exclusion
- Subjects are not permitted to enroll in DV0002 if any of the PS0014 \[NCT03598790\] study exclusion criteria are met
Key Trial Info
Start Date :
December 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 8 2020
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT03766685
Start Date
December 20 2018
End Date
September 8 2020
Last Update
July 14 2025
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Dv0002 946
Phoenix, Arizona, United States, 85032
2
Dv0002 910
Bakersfield, California, United States, 93309
3
Dv0002 955
San Diego, California, United States, 92123
4
Dv0002 943
San Luis Obispo, California, United States, 93405